ABCL
Abcellera Biologics Inc
12.50$
+4.4%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +39.1% | +8.4% | -26.4% | -11.1% | -22.4% | -16.1% | +303.4% | -47.6% | +400.9% | -81.5% | -51.3% | – | |
| – | +22.9% | -25.7% | +462.2% | +0.7% | -63.7% | +205.7% | -83.4% | – | – | +9.3% | – | – | |
| – | +39.1% | +8.4% | -26.4% | -11.1% | -22.4% | -16.1% | +303.4% | -47.6% | +312.4% | -100.9% | – | – | |
| – | +28.2% | -19.2% | +4.2% | +0.1% | +12.5% | -7.8% | -7.7% | +40.3% | -9.0% | -6.8% | -1.4% | – | |
| – | +11.2% | +8.6% | +16.4% | -5.2% | -16.3% | +1.3% | +17.0% | +16.2% | +159.6% | -78.5% | +12.3% | – | |
| – | +22.4% | -13.8% | +55.4% | -0.6% | -22.3% | -14.0% | -0.3% | +27.8% | -23.1% | -12.7% | +16.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.